Exposures to Medical Products

These assessments describe the exposure of individuals to particular medical products, including drugs, devices, or biologics (such as vaccines and blood products) observed in the Mini-Sentinel Distributed Database.

The information is derived from queries of precompiled counts ("summary tables") or by using adaptable standardized programs ("modular programs").

Disclaimer

The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

 

Search by keywords:  

Results from Assessments of Exposures to Medical Products Search
 TitleQuery TypeStatusDate Posted
DetailsVEGF inhibitor use (by generic drug name)Summary table Complete 6-19-2012
DetailsVascular endothelial growth factor (VEGF) inhibitor use (by generic drug name)Modular programComplete 5-09-2013
DetailsSelgiline use Modular ProgramComplete 1-11-2013
DetailsPropylthiouracil and methimazole useSummary table Complete 8-02-2012
DetailsParkinson’s disease medication useModular programComplete 6-07-2013
DetailsOccurrence of selected vaccinations 1Summary table Complete 7-19-2012
DetailsOccurrence of selected pediatric drugs 1Modular programComplete 6-07-2013
DetailsOccurrence of selected generic drugs 6Summary table Complete 1-09-2013
DetailsOccurrence of selected generic drugs 5Summary table Complete 12-14-2012
DetailsOccurrence of selected generic drugs 4Summary table Complete 12-14-2012
DetailsOccurrence of selected generic drugs 3Summary tableComplete 12-14-2012
DetailsOccurrence of Selected Generic Drugs 2Summary table Complete 8-02-2012
DetailsOccurrence of Selected Generic Drugs 1Summary table Complete 8-30-2012
DetailsNatalizumab and efalizumab useSummary tableComplete 12-14-2012
DetailsLindane useSummary table Complete 6-22-2012
DetailsLindane useModular ProgramComplete 1-11-2013
DetailsIsoniazid useSummary table Complete 1-09-2013
DetailsInjection infliximab proceduresSummary table Complete 8-02-2012
DetailsInfliximab UseSummary table Complete 8-02-2012
DetailsGolimumab, ustekinumab, and dronedarone hydrochloride use (by year)Summary tableComplete 12-14-2012
DetailsGolimumab, ustekinumab, and dronedarone hydrochloride use (by quarter)Summary tableComplete 12-14-2012
DetailsDuloxetine, pregabalin, and milnacipran use 1Modular ProgramComplete 1-11-2013
DetailsDuloxetine, pregabalin, and milnacipran use 2Modular ProgramComplete 1-11-2013
DetailsDalfampridine useSummary table Complete 8-02-2012
DetailsDabigatran, rivaroxaban, and warfarin useModular programComplete 5-03-2013
DetailsClozapine use Summary table Complete 6-19-2012
DetailsClopidogrel and prasugrel useModular programComplete 1-11-2013
DetailsBupropion and naltrexone use 2Modular ProgramComplete 1-11-2013
DetailsBupropion and naltrexone use 1Modular ProgramComplete 1-11-2013
DetailsBone resorption inhibitor use (by drug class)Summary table Complete 6-19-2012
DetailsBoceprevir and telaprevir useSummary table Complete 1-09-2013
DetailsAnalgesics useSummary table Complete 8-02-2012
DetailsAmphotericin useSummary table Complete 1-09-2013